157 related articles for article (PubMed ID: 28814674)
1. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist.
Garg M; de Jesus AA; Chapelle D; Dancey P; Herzog R; Rivas-Chacon R; Muskardin TLW; Reed A; Reynolds JC; Goldbach-Mansky R; Sanchez GAM
JCI Insight; 2017 Aug; 2(16):. PubMed ID: 28814674
[TBL] [Abstract][Full Text] [Related]
2. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.
Goldbach-Mansky R; Shroff SD; Wilson M; Snyder C; Plehn S; Barham B; Pham TH; Pucino F; Wesley RA; Papadopoulos JH; Weinstein SP; Mellis SJ; Kastner DL
Arthritis Rheum; 2008 Aug; 58(8):2432-42. PubMed ID: 18668591
[TBL] [Abstract][Full Text] [Related]
3. A case report of a novel compound heterozygous mutation in a Brazilian patient with deficiency of Interleukin-1 receptor antagonist (DIRA).
Mendonça LO; Grossi A; Caroli F; de Oliveira RA; Kalil J; Castro FFM; Pontillo A; Ceccherini I; Barros MAMT; Gattorno M
Pediatr Rheumatol Online J; 2020 Aug; 18(1):67. PubMed ID: 32819369
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study.
Krause K; Weller K; Stefaniak R; Wittkowski H; Altrichter S; Siebenhaar F; Zuberbier T; Maurer M
Allergy; 2012 Jul; 67(7):943-50. PubMed ID: 22583335
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Report of the First Indian Patient and a Novel Deletion Affecting IL1RN.
Mendonca LO; Malle L; Donovan FX; Chandrasekharappa SC; Montealegre Sanchez GA; Garg M; Tedgard U; Castells M; Saini SS; Dutta S; Goldbach-Mansky R; Suri D; Jesus AA
J Clin Immunol; 2017 Jul; 37(5):445-451. PubMed ID: 28503715
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Anakinra Therapy for the Deficiency of Interleukin-1 Receptor Antagonist through Clinical Evidence.
Pillai K; Pillai J; Ling J
J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398338
[TBL] [Abstract][Full Text] [Related]
7. Rilonacept in the treatment of chronic inflammatory disorders.
McDermott MF
Drugs Today (Barc); 2009 Jun; 45(6):423-30. PubMed ID: 19649332
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.
Hoffman HM; Throne ML; Amar NJ; Cartwright RC; Kivitz AJ; Soo Y; Weinstein SP
Clin Ther; 2012 Oct; 34(10):2091-103. PubMed ID: 23031624
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of interleukin-1 with rilonacept is not effective in cold urticaria-Results of a randomized, placebo-controlled study.
Bonnekoh H; Butze M; Spittler S; Staubach P; Weller K; Scheffel J; Maurer M; Krause K
Clin Transl Allergy; 2023 Mar; 13(3):e12226. PubMed ID: 36973954
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.
Lovell DJ; Giannini EH; Reiff AO; Kimura Y; Li S; Hashkes PJ; Wallace CA; Onel KB; Foell D; Wu R; Biedermann S; Hamilton JD; Radin AR
Arthritis Rheum; 2013 Sep; 65(9):2486-96. PubMed ID: 23754188
[TBL] [Abstract][Full Text] [Related]
11. Scoping Review on Use of Drugs Targeting Interleukin 1 Pathway in DIRA and DITRA.
Gómez-García F; Sanz-Cabanillas JL; Viguera-Guerra I; Isla-Tejera B; Nieto AV; Ruano J
Dermatol Ther (Heidelb); 2018 Dec; 8(4):539-556. PubMed ID: 30392030
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD).
Radin A; Marbury T; Osgood G; Belomestnov P
J Clin Pharmacol; 2010 Jul; 50(7):835-41. PubMed ID: 20035038
[TBL] [Abstract][Full Text] [Related]
13. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
14. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A
Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179
[TBL] [Abstract][Full Text] [Related]
15. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
Schumacher HR; Sundy JS; Terkeltaub R; Knapp HR; Mellis SJ; Stahl N; Yancopoulos GD; Soo Y; King-Davis S; Weinstein SP; Radin AR;
Arthritis Rheum; 2012 Mar; 64(3):876-84. PubMed ID: 22223180
[TBL] [Abstract][Full Text] [Related]
16. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
Sundy JS; Schumacher HR; Kivitz A; Weinstein SP; Wu R; King-Davis S; Evans RR
J Rheumatol; 2014 Aug; 41(8):1703-11. PubMed ID: 25028379
[TBL] [Abstract][Full Text] [Related]
17. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
Mitha E; Schumacher HR; Fouche L; Luo SF; Weinstein SP; Yancopoulos GD; Wang J; King-Davis S; Evans RR
Rheumatology (Oxford); 2013 Jul; 52(7):1285-92. PubMed ID: 23485476
[TBL] [Abstract][Full Text] [Related]
18. Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.
Schwier NC
Ann Pharmacother; 2022 May; 56(5):572-581. PubMed ID: 34459270
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial.
Klein AL; Lin D; Cremer PC; Nasir S; Luis SA; Abbate A; Ertel A; LeWinter M; Beutler A; Fang F; Paolini JF
Heart; 2020 Nov; 107(6):488-96. PubMed ID: 33229362
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Inflammatory Diseases with IL-1 Blockade.
Dinarello CA
Curr Otorhinolaryngol Rep; 2018; 6(1):1-14. PubMed ID: 33133777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
